| Full Name |
SARS-Associated Coronavirus Nucleocapsid (1-49)
|
Abbreviated Name-1 |
SARS Coronavirus Nucleocapsid (1-49); SARS-CoV Nucleocapsid(1-49) |
| Documents |
|---|
| Figures |
|---|
| Reference |
|---|
Liu X, et al. Profile of antibodies to the nucleocapsid protein of the severe acute respiratory syndrome (SARS)-associated coronavirus in probable SARS patients. Clinical and diagnostic laboratory immunology. Jan 2004; 11(1): 227-228.
Woo PC, et al. False-positive results in a recombinant severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid enzyme-linked immunosorbent assay due to HCoV-OC43 and HCoV-229E rectified by Western blotting with recombinant SARS-CoV spike polypeptide. J. Clin. Microbiol. Dec 2004; 42(12): 5885-5888.
Yu IM, et al. Crystal structure of the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein dimerization domain reveals evolutionary linkage between corona- and arteriviridae. J. Biol. Chem. Jun 2006; 281(25): 17134-17139.
|
|
Description |
SARS-Associated Coronavirus Nucleocapsid (1-49) is an E. coli-derived recombinant. The protein contains the Nucleocapsid protein immunodominant regions. |
Purity |
Protein is >95% pure as determined by 10% PAGE (coomassie staining). |
Storage |
Protein is shipped at ambient temperature. Upon arrival, store at -20°C. |
Concentration |
1 mg/ml in 50 mM Tris-HCl, 60 mM NaCl, 50% glycerol. |
Stability |
Five year frozen, 6 month at +4°C |
Specificity |
Immunoreactive with sera of SARS-infected individuals. |
Applications |
Antigen in ELISA and Western blots, excellent antigen for detection of SARS with minimal specificity problems. |
Note |
; |
